Plunkett Research Online: AEterna Zentaris Inc

AETERNA ZENTARIS INC (AEZS:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

AEterna Zentaris, Inc. is a Canadian specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The firm’s drug development efforts are focused currently on two compounds, Zoptrex and Macrilen, which are in Phase 3 clinical development, and on an LHRH-.....



AEterna Zentaris Inc
Ticker: AEZS
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 418-652-8525
Fax: 418-652-0881
Address: 315 Sigma Drive
Suite 302D
Summerville, SC 29486 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Drug Development
Oncology Products
Endocrine Therapy Products
ContactsDescription
James ClavijoCFO
Nicola AmmerChief Medical Officer/Vice President, Divisional
See More
AEterna Zentaris, Inc. is a Canadian specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The firm’s drug development efforts are focused currently on two compounds, Zoptrex and Macrilen, which are in Phase 3 clinical development, and on an LHRH-.....See More See More

Auditor: PricewaterhouseCoopers LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Zoptrex
MACRILEN
AEZS-138
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: